Coverage
-
January 29, 2018
Investors who sued Pershing Square Capital Management LP and Valeant Pharmaceuticals over their alleged insider trading scheme ahead of Valeant's failed $55 billion effort to acquire Allergan Inc. filed papers Friday to begin the approval process for $290 million in settlements.
15 other articles on this case.
View all »